A phase 1 clinical pharmacological study with repeated oral doses of KAG-308
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2014
Price : $35 *
At a glance
- Drugs KAG 308 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Kaken Pharmaceutical
- 14 Oct 2014 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan .
- 26 May 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 21 May 2014 New trial record